Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up

Merck (MRK) is back in focus after announcing that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial. See our latest analysis for Merck. Merck’s recent mRNA melanoma result has arrived alongside powerful price momentum, with a 30 day share price return of 18.0% and a year to date share price return of 40.0%. The 1 year total shareholder return...